ImpediMed Limited

ASX:IPD Stock Report

Market Cap: AU$103.2m

ImpediMed Valuation

Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IPD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPD?

Key metric: As IPD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IPD. This is calculated by dividing IPD's market cap by their current revenue.
What is IPD's PS Ratio?
PS Ratio10x
SalesAU$10.32m
Market CapAU$103.20m

Price to Sales Ratio vs Peers

How does IPD's PS Ratio compare to its peers?

The above table shows the PS ratio for IPD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.3x
SOM SomnoMed
1x10.2%AU$91.8m
OIL Optiscan Imaging
47.6xn/aAU$142.0m
AHC Austco Healthcare
1.7xn/aAU$98.3m
CYC Cyclopharm
7x42.7%AU$167.8m
IPD ImpediMed
10x41.0%AU$103.2m

Price-To-Sales vs Peers: IPD is good value based on its Price-To-Sales Ratio (10x) compared to the peer average (14.3x).

Price to Sales Ratio vs Industry

How does IPD's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
SDI SDI
1.3x5.4%US$87.72m
SOM SomnoMed
1x10.2%US$57.44m
CMP Compumedics
1xn/aUS$30.46m
NXS Next Science
0.9x30.6%US$21.93m
IPD 10.0xIndustry Avg. 4.0xNo. of Companies11PS0612182430+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (10x) compared to the Australian Medical Equipment industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10x
Fair PS Ratio15.5x

Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (10x) compared to the estimated Fair Price-To-Sales Ratio (15.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.051
AU$0.15
+185.6%
27.0%AU$0.19AU$0.09n/a4
Dec ’25AU$0.051
AU$0.15
+185.6%
27.0%AU$0.19AU$0.09n/a4
Nov ’25AU$0.055
AU$0.15
+164.9%
27.0%AU$0.19AU$0.09n/a4
Oct ’25AU$0.059
AU$0.15
+158.0%
26.4%AU$0.20AU$0.09n/a4
Sep ’25AU$0.048
AU$0.16
+243.1%
13.9%AU$0.20AU$0.14n/a4
Aug ’25AU$0.06
AU$0.17
+178.1%
14.2%AU$0.20AU$0.14n/a4
Jul ’25AU$0.071
AU$0.18
+146.9%
15.0%AU$0.20AU$0.14n/a4
Jun ’25AU$0.076
AU$0.18
+130.7%
15.0%AU$0.20AU$0.14n/a4
May ’25AU$0.08
AU$0.18
+119.2%
15.0%AU$0.20AU$0.14n/a4
Apr ’25AU$0.092
AU$0.18
+97.1%
16.2%AU$0.20AU$0.14n/a3
Mar ’25AU$0.093
AU$0.18
+95.0%
16.2%AU$0.20AU$0.14n/a3
Feb ’25AU$0.10
AU$0.22
+105.5%
16.2%AU$0.26AU$0.18n/a3
Jan ’25AU$0.14
AU$0.22
+51.7%
15.5%AU$0.26AU$0.18n/a3
Dec ’24AU$0.14
AU$0.22
+57.1%
15.5%AU$0.26AU$0.18AU$0.0513
Nov ’24AU$0.10
AU$0.27
+159.2%
30.6%AU$0.39AU$0.21AU$0.0553
Oct ’24AU$0.17
AU$0.23
+29.1%
52.4%AU$0.39AU$0.06AU$0.0594
Sep ’24AU$0.17
AU$0.23
+32.9%
52.4%AU$0.39AU$0.06AU$0.0484
Aug ’24AU$0.20
AU$0.24
+22.6%
49.6%AU$0.39AU$0.06AU$0.064
Jul ’24AU$0.18
AU$0.17
-8.3%
37.0%AU$0.21AU$0.06AU$0.0714
Jun ’24AU$0.14
AU$0.17
+18.0%
37.0%AU$0.21AU$0.06AU$0.0764
May ’24AU$0.17
AU$0.16
-1.5%
38.3%AU$0.23AU$0.06AU$0.084
Apr ’24AU$0.10
AU$0.18
+74.6%
19.6%AU$0.23AU$0.14AU$0.0923
Mar ’24AU$0.061
AU$0.15
+141.3%
47.1%AU$0.23AU$0.04AU$0.0934
Feb ’24AU$0.061
AU$0.17
+170.6%
56.4%AU$0.30AU$0.04AU$0.104
Jan ’24AU$0.079
AU$0.18
+126.3%
51.7%AU$0.30AU$0.04AU$0.144
Dec ’23AU$0.092
AU$0.18
+94.3%
51.7%AU$0.30AU$0.04AU$0.144

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImpediMed Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
Matthijs SmithCanaccord Genuity